Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-01-05 Diabetic nephropathy
| Finerenone Kerendia® |
|
Formulary
|
Tablets 10mg, 20mg |
 NICE TA877: Finerenone for treating chronic kidney disease in type 2 diabetes |
|
Links
Biosimilars policy statement- Diabetes UK: Diabetes when you’re unwell
- LSCMMG: Diabetes - Choice of Safety Pen Needles and Lancets
- LSCMMG: Diabetes - Pen Needles/Lancets
- LSCMMG: Diabetes - Position Statement Safety Needles and Safety Lancets
- LSCMMG: Diabetes Guideline for antihyperglycaemic therapy in adults with type 2 diabetes
- LSCMMG: Diabetes: Recommended meters, strips and devices
LSCMMG: GLP-1 patient contract- LSCMMG: Osteoporosis: Secondary fracture prevention patient treatment pathway
- LSCMMG: Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus
- LSCMMG: Trans Female Gender Dysphoria Information Sheet
- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- MHRA: Diabetes and driving
- NHSE guidance to primary care about unregulated providers who supply hormone medications to children and young people for gender incongruence
- NICE NG17: Type 1 diabetes in adults: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- NICE TA877: Finerenone for treating chronic kidney disease in type 2 diabetes